Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01260467 · ClinicalTrials.gov registry record · Phase 2
Memantine for Recurrent Glioblastoma
A Phase 2 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01260467 is a Phase 2 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 4 participants.
The verdict
NCT01260467, a Phase 2 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a medication called memantine is effective in treating glioblastoma. Memantine targets a specific receptor, called a glutamate receptor, which is thought to be involved in the growth of brain tumors. It has previously been studied for other types of conditions, such as Alzheimer's disease, but it has not yet been evaluated in the treatment of brain tumors. The investigators will also be determining how common it is for patients with brain tumors to have side effects to memantine. Memantine will be taken by mouth twice a day.
Interventions
- DRUG memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01260467
The ClinicalTrials.gov registry entry for NCT01260467 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which memantine is the first listed.
NCT01260467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01260467 about?
NCT01260467 is a clinical study titled "Memantine for Recurrent Glioblastoma". The purpose of this study is to determine if a medication called memantine is effective in treating glioblastoma. Memantine targets a specific receptor, called a glutamate receptor, which is thought to be involved in the growth of brain tumors. It has previously been studied for other types of condi...
What is the current status of trial NCT01260467?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2010-11. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01260467?
The interventions under investigation include: memantine (DRUG).
Who is sponsoring clinical trial NCT01260467?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.